Carmen Palomino-Cano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmen Palomino-Cano has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Javier Carrión
ICPVet Research Group, Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain
2 shared publications - Socorro Espuelas
University of Navarra
2 shared publications - Carlos Torrado-Salmerón
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
1 shared publication - Christophe Dardonville
Institute of Medicinal Chemistry, IQM-CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
1 shared publication - Dolores Remedios Serrano
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
1 shared publication Esther Larrea
Department of Molecular Biology. School of Sciences University of Navarra Pamplona Spain
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6181
Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis
Cutaneous leishmaniosis (CL) remains a major neglected tropical disease, with current therapies constrained by toxicity, high cost, and variable efficacy. Here, we evaluated an immunochemotherapy strategy combining topical amphotericin B (AmB) with the therapeutic DNA vaccine HisAK70 in a murine model of Leishmania major infection. BALB/c mice were subcutaneously infected and treated with topical AmB cream alone, AmB plus HisAK70, or paromomycin (PM) as a reference therapy. Therapeutic efficacy was assessed through lesion progression, parasite burden in draining lymph nodes and spleen, and immunological markers associated with parasite control. Both PM and the combined AmB + HisAK70 treatment significantly reduced lesion progression and markedly decreased parasite burden compared with infected controls, demonstrating effective control of local infection and systemic dissemination. Importantly, the combination therapy enhanced the efficacy of AmB alone, supporting the beneficial contribution of vaccine-driven immune modulation to therapeutic outcome. Therapeutic efficacy was associated with reduced arginase activity in infected tissues and an increased IFN-γ/IL-4 ratio, indicative of a protective Th1-oriented immune response. Together, these findings highlight immunochemotherapy as a promising strategy for CL treatment, integrating localized topical drug delivery with targeted immune activation to improve therapeutic efficacy while potentially reducing systemic toxicity.
- 10 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (14) , 6181
Open AccessImmunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis
Cutaneous leishmaniosis (CL) remains a major neglected tropical disease, with current therapies constrained by toxicity, high cost, and variable efficacy. Here, we evaluated an immunochemotherapy strategy combining topical amphotericin B (AmB) with the therapeutic DNA vaccine HisAK70 in a murine model of Leishmania major infection. BALB/c mice were subcutaneously infected and treated with topical AmB cream alone, AmB plus HisAK70, or paromomycin (PM) as a reference therapy. Therapeutic efficacy was assessed through lesion progression, parasite burden in draining lymph nodes and spleen, and immunological markers associated with parasite control. Both PM and the combined AmB + HisAK70 treatment significantly reduced lesion progression and markedly decreased parasite burden compared with infected controls, demonstrating effective control of local infection and systemic dissemination. Importantly, the combination therapy enhanced the efficacy of AmB alone, supporting the beneficial contribution of vaccine-driven immune modulation to therapeutic outcome. Therapeutic efficacy was associated with reduced arginase activity in infected tissues and an increased IFN-γ/IL-4 ratio, indicative of a protective Th1-oriented immune response. Together, these findings highlight immunochemotherapy as a promising strategy for CL treatment, integrating localized topical drug delivery with targeted immune activation to improve therapeutic efficacy while potentially reducing systemic toxicity.
- Open Access
- 6 July 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (30) , e71415
Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden
Cutaneous leishmaniasis (CL) remains difficult to treat because Leishmania parasites persist within dermal macrophages and suppress their microbicidal activity, promoting chronic infection. Toll‐like receptor (TLR) agonists can restore macrophage effector functions, but their therapeutic use is limited by systemic toxicity. Here, we developed a lipid‐based nanoemulsion (NE) for the systemic delivery of the TLR7 agonist gardiquimod (GDQM) to improve macrophage targeting and reduce off‐target inflammatory effects. Following intravenous administration, GDQM‐NEs efficiently accumulated in dermal lesions and significantly reduced systemic cytokine release compared with free GDQM, resulting in an improved safety profile. Importantly, nanoencapsulation preserved GDQM antileishmanial activity achieving an approximately 2‐log reduction in parasite burden. Treatment induced both Th1‐associated cytokines (IFN‐γ and IL‐12p70) and regulatory responses, including IL‐10 production and FoxP3 + regulatory T‐cell expansion. Despite efficient lesion accumulation, CD86 upregulation was detected in macrophages from draining lymph nodes (dLNs) but not at the lesion site, indicating limited local macrophage activation. These findings indicate that GDQM‐NEs effectively overcome major delivery and safety barriers associated with systemic TLR7 agonist administration, whereas the lesion microenvironment and TLR‐driven regulatory mechanisms remain key constraints on therapeutic efficacy. Combining TLR agonists with strategies that counteract these local suppressive pathways may further enhance treatment outcomes in CL.
- 6 July 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (30) , e71415
Open AccessGardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden
Cutaneous leishmaniasis (CL) remains difficult to treat because Leishmania parasites persist within dermal macrophages and suppress their microbicidal activity, promoting chronic infection. Toll‐like receptor (TLR) agonists can restore macrophage effector functions, but their therapeutic use is limited by systemic toxicity. Here, we developed a lipid‐based nanoemulsion (NE) for the systemic delivery of the TLR7 agonist gardiquimod (GDQM) to improve macrophage targeting and reduce off‐target inflammatory effects. Following intravenous administration, GDQM‐NEs efficiently accumulated in dermal lesions and significantly reduced systemic cytokine release compared with free GDQM, resulting in an improved safety profile. Importantly, nanoencapsulation preserved GDQM antileishmanial activity achieving an approximately 2‐log reduction in parasite burden. Treatment induced both Th1‐associated cytokines (IFN‐γ and IL‐12p70) and regulatory responses, including IL‐10 production and FoxP3 + regulatory T‐cell expansion. Despite efficient lesion accumulation, CD86 upregulation was detected in macrophages from draining lymph nodes (dLNs) but not at the lesion site, indicating limited local macrophage activation. These findings indicate that GDQM‐NEs effectively overcome major delivery and safety barriers associated with systemic TLR7 agonist administration, whereas the lesion microenvironment and TLR‐driven regulatory mechanisms remain key constraints on therapeutic efficacy. Combining TLR agonists with strategies that counteract these local suppressive pathways may further enhance treatment outcomes in CL.